JD
Therapeutic Areas
Kyowa Kirin Pipeline
| Drug | Indication | Phase |
|---|---|---|
| POTELIGEO (mogamulizumab) | Cutaneous T-cell lymphoma (CTCL) | Marketed |
| CRYSVITA (burosumab) | X-linked hypophosphatemia (XLH) | Marketed |
| KW-0761 (mogamulizumab) | Adult T-cell leukemia-lymphoma (ATLL) | Phase III |
| Libmeldy (atidarsagene autotemcel) | Metachromatic leukodystrophy (MLD) | Marketed |
| KHK4083 | Atopic dermatitis | Phase III |
| KW-6356 | Parkinson's disease (dyskinesia) | Phase III |
| HSC-GT for MPS-I | Hurler syndrome (MPS-IH) | Phase I/II |
| HSC-GT for MPS-IIIA | Sanfilippo syndrome type A | Preclinical |